Summary of Significant Accounting Policies (Details Narrative) - USD ($) |
9 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|
Sep. 30, 2021 |
Dec. 31, 2020 |
Dec. 31, 2019 |
Aug. 17, 2021 |
Jun. 30, 2020 |
|
| Depreciation and amortization expense | $ 0 | $ 322 | $ 1,355 | ||
| Deferred offering costs | $ 2,600,000 | ||||
| Patent cost | 74,920 | 32,411 | |||
| Research and developement expenses | $ 2,623,280 | $ 1,607,819 | |||
| Warrant [Member] | IPO [Member] | |||||
| Offering price | $ 7.00 | ||||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|